Page 84 - Read Online

Osho et al. Hepatoma Res 2020;6:55 I http://dx.doi.org/10.20517/2394-5079.2020.42 Page 13 of 15

tomography -- a randomised study. Aliment Pharmacol Ther 2013;38:303-12.
36. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, et al. Hepatocellular carcinoma surveillance: an evidence-based approach.
World J Gastroenterol 2019;25:1550-9.
37. Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma
in patients with cirrhosis. Clin Gastroenterol Hepatol 2008;6:1418-24.
38. Kim SY, An J, Lim YS, Han S, Lee JY, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of
hepatocellular carcinoma. JAMA Oncol 2017;3:456-63.
39. Kim HL, An J, Park JA, Park SH, Lim YS, et al. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance
in high-risk patients with cirrhosis. Hepatology 2019;69:1599-613.
40. Lee JY, Huo EJ, Weinstein S, Santos C, Monto A, et al. Evaluation of an abbreviated screening MRI protocol for patients at risk for
hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:1627-33.
41. Khatri G, Pedrosa I, Ananthakrishnan L, de Leon AD, Fetzer DT, et al. Abbreviated-protocol screening MRI vs. complete-protocol
diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018. J Magn
Reson Imaging 2020;51:415-25.
42. Park HJ, Jang HY, Kim SY, Lee SJ, Won HJ, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular
carcinoma: comparison with ultrasound. J Hepatol 2020;72:718-24.
43. An C, Kim DY, Choi JY, Han KH, Roh YH, et al. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular
carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. BMC Cancer 2018;18:915.
44. Kim HA, Kim KA, Choi JI, Lee JM, Lee CH, et al. Comparison of biannual ultrasonography and annual non-contrast liver magnetic
resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.
BMC Cancer 2017;17:877.
45. Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, et al. Prognostic gene expression signature for patients with hepatitis C-related
early-stage cirrhosis. Gastroenterology 2013;144:1024-30.
46. Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related
cirrhosis for risk stratification. J Hepatol 2019;71:523-33.
47. Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?
Curr Hepatol Rep 2017;16:64-71.
48. Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, et al. Utilization of hepatocellular carcinoma surveillance among American
patients: a systematic review. J Gen Intern Med 2012;27:861-7.
49. Singal AG, Li X, Tiro J, Kandunoori P, Adams-Huet B, et al. Racial, social, and clinical determinants of hepatocellular carcinoma
surveillance. Am J Med 2015;128:90.e1-7.
50. Farvardin S, Patel J, Khambaty M, Yerokun OA, Mok H, et al. Patient-reported barriers are associated with lower hepatocellular
carcinoma surveillance rates in patients with cirrhosis. Hepatology 2017;65:875-84.
51. Simmons OL, Feng Y, Parikh ND, Singal AG. Primary care provider practice patterns and barriers to hepatocellular carcinoma
surveillance. Clin Gastroenterol Hepatol 2019;17:766-73.
52. Beste LA, Ioannou GN, Yang Y, Chang MF, Ross D, et al. Improved surveillance for hepatocellular carcinoma with a primary care-
oriented clinical reminder. Clin Gastroenterol Hepatol 2015;13:172-9.
53. Singal AG, Tiro JA, Murphy CC, Marrero JA, McCallister K, et al. Mailed outreach invitations significantly improve HCC surveillance
rates in patients with cirrhosis: a randomized clinical trial. Hepatology 2019;69:121-30.
54. Singal AG, Tiro JA, Marrero JA, McCallister K, Mejias C, et al. Mailed outreach program increases ultrasound screening of patients with
cirrhosis for hepatocellular carcinoma. Gastroenterology 2017;152:608-15.e4.
55. Fetzer DT, Rodgers SK, Harris AC, Kono Y, Wasnik AP, et al. Screening and surveillance of hepatocellular carcinoma: an introduction to
ultrasound liver imaging reporting and data system. Radiol Clin North Am 2017;55:1197-209.
56. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic
patients with an arterially-enhancing liver mass. Liver Transpl 2005;11:281-9.
57. Tang A, Bashir MR, Corwin MT, Cruite I, Dietrich CF, et al; LI-RADS Evidence Working Group. Evidence supporting LI-RADS major
features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: a systematic review. Radiology 2018;286:29-48.
58. Elsayes KM, Kielar AZ, Chernyak V, Morshid A, Furlan A, et al. LI-RADS: a conceptual and historical review from its beginning to its
recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 2019;6:49-69.
59. van der Pol CB, Lim CS, Sirlin CB, McGrath TA, Salameh JP, et al. Accuracy of the liver imaging reporting and data system in
computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review.
Gastroenterology 2019;156:976-86.
60. Shao S, Liang Y, Kuang S, Chen J, Shan Q, et al. Diagnostic performance of LI-RADS version 2018 in differentiating hepatocellular
carcinoma from other hepatic malignancies in patients with hepatitis B virus infection. Bosn J Basic Med Sci 2020;20:401-10.
61. Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review
and meta-analysis. Hepatology 2018;67:401-21.
62. Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR
imaging-a systematic review and meta-analysis. Radiology 2015;275:97-109.
63. Kim JY, Kim MJ, Kim KA, Jeong HT, Park YN. Hyperintense HCC on hepatobiliary phase images of gadoxetic acid-enhanced MRI:
correlation with clinical and pathological features. Eur J Radiol 2012;81:3877-82.